Biofrontera Inc. Finalizes Acquisition of Ameluz® and RhodoLED®
Biofrontera Inc. has successfully completed the acquisition of all U.S. rights to its key products, Ameluz® and RhodoLED®, enhancing its position within the biopharmaceutical market. This pivotal move involves obtaining complete control over the New Drug Application (NDA) and all associated patents previously held by its former parent company, Biofrontera AG.
Transformative Deal Details
The finalized agreement includes a new earnout structure which is set to lower the payment rate to a more manageable 12%–15% of U.S. net sales, down from the prior rate of 25%–35%. This strategic adjustment is expected to significantly reduce ongoing costs and facilitate a faster pathway to profitability for Biofrontera Inc.
With the conclusion of this acquisition, Biofrontera Inc. is now responsible for the complete lifecycle of Ameluz® and the RhodoLED® product lines, including key areas such as manufacturing, regulatory compliance, and marketing strategies. This change reflects the company's intent to strengthen its operational framework while also strategically positioning itself for future growth in the dermatological treatment space.
Funding and Financial Implications
The transaction has been financially backed by an $11 million investment led by existing investors. This capital infusion is expected to provide vital support for Biofrontera as it moves toward achieving profitability. A portion of the funds, specifically $8.5 million, was secured at the time the term sheet was executed.
In conjunction with this deal, Biofrontera AG has gained a 10% equity stake in Biofrontera Inc., which aligns the long-term interests of both companies and potentially opens up opportunities for future collaborations.
Management Insights
Dr. Hermann Luebbert, the Chief Executive Officer of Biofrontera Inc., expressed enthusiasm regarding the acquisition, noting it as a transformative deal that is poised to enhance the company's financial and operational dynamics. He stated that the reduced earnout rates are anticipated to substantially improve gross margins, particularly from the fourth quarter of the year onward. Coupled with the newly acquired funding, this positions Biofrontera to bolster growth efforts surrounding Ameluz® and aims to expand its application into additional treatment areas.
About Biofrontera Inc.
Biofrontera Inc. focuses heavily on the development and commercialization of photodynamic therapy (PDT) for dermatological conditions. By harnessing the unique properties of Ameluz® in conjunction with the RhodoLED® lamp system, the company aims to treat actinic keratosis and various forms of skin cancer effectively. The ongoing clinical trials showcase Biofrontera’s ambition to broaden the application of its products, potentially addressing more severe skin conditions and even acne.
Frequently Asked Questions
What assets did Biofrontera Inc. acquire from Biofrontera AG?
Biofrontera Inc. acquired full U.S. rights to Ameluz® and RhodoLED®, including all intellectual property, NDAs, and associated patents.
How will the new earnout structure affect Biofrontera Inc. financially?
The new earnout structure reduces payments to 12%–15% of U.S. net sales, which is expected to lower costs and accelerate the company's path to profitability.
What are Biofrontera Inc.'s plans for Ameluz® and RhodoLED® moving forward?
Biofrontera Inc. plans to take full control over manufacturing, regulatory compliance, and marketing for these products, with intentions to expand their applications in dermatology.
Who is funding the acquisition deal?
The acquisition has been financed through an $11 million investment led by Rosalind Advisors and AIGH Capital Management.
How does this acquisition impact shareholders?
With a 10% equity stake in Biofrontera Inc. granted to Biofrontera AG, this acquisition is designed to enhance shareholder value through improved operational efficiency and profitability.
